Olverembatinib in Patients with Pretreated/Refractory CML

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

For patients with acute lymphoblastic leukemia and mantle cell leukemia, lymphodepletion then brexu-cel show positive efficacy and safety outcomes.

Elizabeth Shpall, MD

May 29th 2019

Asciminib Boosts Efficacy Vs TKIs in Chronic Myeloid Leukemia

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

Data from the phase 3 ASC4FIRST trial support asciminib as a standard of care in newly diagnosed chronic myeloid leukemia in chronic phase.

Megan Hollasch

Immunotherapy Approaches in AML

Data from the phase 3 ASC4FIRST trial support asciminib as a standard of care in newly diagnosed chronic myeloid leukemia in chronic phase.

Naval Daver, MD

January 17th 2019

Efficacy Demonstrated Using Olverembatinib in Chronic-Phase CML

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

Olverembatinib appears effective in patients with CP-CML without T315I mutations following prior first-line tyrosine kinase inhibitor therapy.

Alex Biese

Socioeconomic Barriers Limit Access to Lifesaving Stem Cell Transplants in AML

Olverembatinib appears effective in patients with CP-CML without T315I mutations following prior first-line tyrosine kinase inhibitor therapy.

Addressing socioeconomic barriers may help ensure that all patients with AML can benefit from potentially curative therapies.

Silas Inman

Non-Relapse Mortality Rates in B-ALL and MCL Consistent With Lymphodepletion/Brexu-Cel Treatment

Addressing socioeconomic barriers may help ensure that all patients with AML can benefit from potentially curative therapies.

Related Content

Chris Ryan

December 9th 2024

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

For patients with acute lymphoblastic leukemia and mantle cell leukemia, lymphodepletion then brexu-cel show positive efficacy and safety outcomes.

Elizabeth Shpall, MD

May 29th 2019

Asciminib Boosts Efficacy Vs TKIs in Chronic Myeloid Leukemia

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

Megan Hollasch

Immunotherapy Approaches in AML

Data from the phase 3 ASC4FIRST trial support asciminib as a standard of care in newly diagnosed chronic myeloid leukemia in chronic phase.

Naval Daver, MD

January 17th 2019